Home India Ministry of Chemicals and Fertilizers Corrigendum in respect of SO 5496(E) dated 19.12.2024 relate...
Date: 07-Feb-2025 Category: Extra Ordinary State: Union Government Country: India

Corrigendum in respect of SO 5496(E) dated 19.12.2024 related to fixation of separate ceiling price of Synchrobreathe Device

Issued by Ministry of Chemicals and Fertilizers · Department of Pharmaceuticals

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

What it means

  • This gazette notification is a corrigendum issued by the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, regarding a previous notification S.O. 5496(E) dated 19.12.2024. The corrigendum specifically addresses an error in the stated ceiling price for 'Synchrobreathe Inhaler' manufactured by M/s Cipla Ltd.

Key Changes

  • The ceiling price for Synchrobreathe Inhaler (Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler) has been revised.
  • The incorrect price of Rs. 41.20 per inhaler is replaced with the correct price of Rs. 81.20 per inhaler.
  • All other contents and notes mentioned in the original order S.O. 5496(E) dated 19.12.2024 remain unchanged.

Impact Analysis

M/s Cipla Ltd

  • Cipla needs to communicate the price change to its distribution network.

Retailers and Pharmacies

  • They should be aware of the change to avoid overcharging customers.

Consumers

  • This corrects the previously lower stated price.

National Pharmaceutical Pricing Authority (NPPA)

  • NPPA should monitor compliance with the revised ceiling price.

Key Entities Referenced

National Pharmaceutical Pricing Authority (NPPA): A regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for price control of pharmaceutical products in India. M/s Cipla Ltd: A pharmaceutical company manufacturing Synchrobreathe Inhaler. S.O. 5496(E): The original notification dated 19.12.2024 which this corrigendum amends. Synchrobreathe Inhaler: Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler. The pharmaceutical product whose price is being corrected.
Official Source Record View Original Source →
See Full Document Text
रजिस्ट्री स.ं डी.एल.- 33004/99 REGD. No. D. L.-33004/99 सी.जी.-डी.एल.-अ.-07022025-260824 CG-DxLx-xEG-I0D7H0x2x2x0 25-260824 xxxGIDExxx असाधारण EXTRAORDINARY भाग II—खण् ड 3—उप-खण्ड (ii) PART II—Section 3—Sub-section (ii) प्राजधकार स ेप्रकाजित PUBLISHED BY AUTHORITY स.ं 658] नई दिल्ली, िुक्रर्ार, फरर्री 7, 2025/माघ 18, 1946 No. 658] NEW DELHI, FRIDAY, FEBRUARY 7, 2025/MAGHA 18, 1946 रसायन और उर्रव क मत्रं ालय (औषध जर्भाग) (राष्ट्रीय औषध मल्ू य जनधारव ण प्राजधकरण) िजु ि-पत्र नई दिल्ली, 7 फरर्री, 2025 का.आ. 662(अ).—भारत के असाधारण, रािपत्र म ें प्रकाजित, दिनांक 19.12.2024 के राष्ट्रीय औषध मूल्य जनधावरण प्राजधकरण की अजधसचू ना का. आ. 5496(अ), िो दक पैरा 11(3) के तहत मेससव जसप्ला जलजमटेड के 'ससंक्रोब्रीि इनहले र जडर्ाइस' के अलग-अलग मूल्य जनधावरण से संबंजधत ह,ै के ताजलका की संख्या 2, सहिं ी और अंग्रेिी िोनों का रूपांतरण जनम्नानुसार पढ़ िाए। इसके स्ट्थान पर क्रम सं. फॉमूवलेिन इकाई कॉलम (2) म ेंफॉमलूव ेिन के संबधं म ेंससक्रं ोब्रीथ इनहले र की अलग अजधकतम कीमत(रूपए में) (1) (2) (3) (4) 2 एक इनहेलर में 200 खुराक के जलए बुडेसोनाइड इनहेलेिन 1 इनहले र 41.20 (एमडीआई) 200 एमसीिी/खुराक के जलए ससक्रं ोब्रीथ इनहेलर 964 GI/2025 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] इस प्रकार पढ़ा िाए क्रम सं. फॉमूवलेिन कॉलम (2) म ेंफॉमलूव ेिन के संबधं म ेंससक्रं ोब्रीथ इकाई इनहले र की अलग अजधकतम कीमत(रूपए में) (1) (2) (3) (4) 2 एक इनहेलर में 200 खुराक के जलए बुडेसोनाइड इनहेलेिन 1 इनहले र 81.20 (एमडीआई) 200 एमसीिी/खुराक के जलए ससक्रं ोब्रीथ इनहेलर दिनांक 19.12.2024 के मलू आिेि का.आ. 5496(अ), मे उल्लेजखत सभी नोट्स और अन्य सामग्री समान रहगे ी । [पीएन/261/129/2025/एफ/फा. स.ं 8(129)/2025/डी.पी./एनपीपीए-जडर्ीिन-II] महार्ीर सैनी, उप जनिेिक MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) CORRIGENDUM New Delhi, the 7th February, 2025 S.O. 662(E).— In the National Pharmaceutical Pricing Authority's notification S.O. 5496(E) dated 19.12.2024 in relation to the fixation separate price of Synchrobreathe Inhaler Device for M/s Cipla Ltd under Para 11(3), published in the Gazette of India, Extraordinary, the Entry at Sl. No. 2 of the Table, both in Hindi & English version, be read as follows: Instead of S. Formulation Unit Separate Ceiling Price of Synchrobreathe No. Inhaler in respect of formulations in column (2) (in Rs.) (1) (2) (3) (4) 2 Synchrobreathe Inhaler for Budesonide 1 inhaler 41.20 Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler Read as S. Formulation Unit Separate Ceiling Price of Synchrobreathe No. Inhaler in respect of formulations in column (2) (in Rs.) (1) (2) (3) (4) 2 Synchrobreathe Inhaler for 1 inhaler 81.20 Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler All the notes and other contents mentioned in the original order S.O. 5496(E) dated 19.12.2024 shall remain the same [PN/261/129/2025/F/F. No. 8(129)/2025/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.

Continue your research